Advertisement

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

First International Summit on Interventional Pharmacoeconomics

Advertisement

Related Videos

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Amit Sanyal, MD: A Clinician’s Perspective

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Advertisement

Advertisement

Jun

01

Today In Oncology

After the Founder: What a Cervical Cancer Program in Haiti Teaches About Sustaining Prevention

Pain and Health-Related QOL With Darolutamide in Metastatic Hormone-Sensitive Prostate Cancer

Lymph Node Surgery and CDK4/6 Inhibitor Treatment in Early Breast Cancer

ASCO Collaborates With Ryght AI to Accelerate Site Selection for Metastatic Breast Cancer Trial

Behind the Scenes of the 2026 ASCO Annual Meeting

Advertisement

© 2026 HSP News Service, L.L.C.